Biogen Partners With LigoCyte On Anti-CD103 Target
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies will pursue development of treatments for respiratory, gastrointestinal and autoimmune indications.
You may also be interested in...
Biogen Idec Partners With Cardiokine On Vasopressin Antagonist For Hyponatremia
Phase III trials of the oral drug, which will start this year, are expected to take two years to complete, Biogen says.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.